Humaid Al-Shamsi, Chairman of Nexomic, shared on LinkedIn:
“Which institution or biotech company has the highest number of scientific contributions to European Society for Medical Oncology AI in Berlin?
Nexomic!
Heading from Dubai via Doha to Berlin to lead the largest scientific contribution to ESMO AI, with 10 presentations including 9 abstracts and 1 oral presentation from Nexomic.
Our research introduces innovative AI-driven approaches and biomarker discovery to improve cancer diagnosis and personalize treatment for various solid tumors.
Proud of our exceptional team of 25 PhDs and postdoctoral scientists, whose dedication over the past year made this significant milestone possible.
Looking to meet you all there & work together to cure advanced cancer one day.”
You can also read:
ESMO AI 2026 Offers an Opportunity to Explore How Real-World Data Is Transforming Oncology